Tarsus Pharmaceuticals (NASDAQ:TARS) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for a variety of eye conditions. The company works on breakthrough treatments aimed at addressing significant unmet medical needs in ocular health. Among its key projects is the development of a pioneering solution for Demodex blepharitis, a common eyelid condition that Tarsus is targeting with its flagship drug candidate. This initiative highlights the company's commitment to transforming patient care in ophthalmology. Additionally, Tarsus Pharmaceuticals explores treatments for other eye diseases, underscoring its objective to become a leader in eye care solutions by delivering novel and effective therapies to patients worldwide.